MacroGenics reported $16.82M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Genmab DKK 336M 141M Jun/2025
Geron USD -31.14M 12.72M Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
J&J USD 5.12B 36M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
MacroGenics USD 16.82M 53.07M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Xencor USD -6.65M 626K Dec/2025